What is known and objectives: Most antineoplastic drugs are highly toxic and have low therapeutic indexes, which can result in drug-related problems. In this context, pharmacist interventions may play an important role in the success of the treatment.
Added to clinical burden, this disease imposes a substantial economic burden on society, with the cost estimated to be up to 4% of global gross domestic product. 3 Thus, strategies to address the screening, diagnosis, treatment and palliation needs of cancer patients are required and should be considered as a sound investment by governments. 4 Drugs play an important role in cancer treatment; however, most antineoplastic drugs have high toxicity and low therapeutic indexes, resulting in drug-related problems that often need dose adjustments and analysis of potential drug interactions. 5 Moreover, medication adherence in patients with cancer might be low and influenced by several factors, such as the patient's values, lifestyle and beliefs, access to health services and factors related to drug therapy (eg, greater number of medications prescribed and undesirable adverse effects). 6 The knowledge and skills of an oncology pharmacist could support a wide variety of functions in all aspects of patient care. This professional is often one of the few healthcare team members who fully understands the safety, efficacy and pharmacologic and financial components of care of patients with cancer. 7 Given this context, pharmacists have become more proactive as they have been integrated into care teams, participating directly in the selection and management of patients' drug therapy, as well as proving drug counselling for patients and other health professionals. 7, 8 A previous systematic review 9 explored the role of pharmacists in communicating to people living with cancer about their use of complementary medicines, whereas another review 10 assessed models of pharmacist interventions in assisting oncology patients. However, to the best our knowledge, summarized evidence on the effect of pharmacist interventions in outpatients with cancer is lacking in the current literature. In order to address this gap, the purpose of this systematic review was to describe and examine the effect of pharmacist interventions on health outcome measures of adult outpatients with cancer using antineoplastic drugs. In addition, we screened the reference lists of appraised articles to identify any studies that might have been missed. The method of analysis and inclusion criteria for this review were specified in advance and documented in a protocol available upon request from the corresponding author.
| METHODS
To be included in this review, the articles had to meet the following criteria: (i) be an original article (ie, randomized controlled trials, non-randomized controlled studies, cohort studies, cross-over studies, before-and-after studies); (ii) be published in Portuguese, Spanish or English; (iii) have evaluated the effect of pharmacist interventions in the clinical pharmacy services (ie, activities in which the pharmacist makes a clinical decision-making process aimed at improving the patients' health outcomes); (iv) report possible changes over time in outcome measures (ie, changes from pre-to post-pharmacist inter- 
| RESULTS
A total of 874 potentially relevant records were identified from the databases. After reviewing the titles and abstracts, 617 records were excluded because they did not include a study of pharmacist interventions in adult patients with cancer; did not assess the impact of interventions; or included non-ambulatory patients. The remaining 40 records were selected for full-text examination, of which 11 met all the eligibility criteria and were included in this systematic review.
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The excluded studies and the reasons for their exclusion are detailed in Appendix 2. A flow chart of the selection process of studies per inclusion and exclusion criteria is shown in Figure 1 .
Characteristics of the 11 studies included in this systematic review are shown in Table 1 . Studies were conducted in the United States of America (n=3), [18] [19] [20] Spain (n=2), 16, 21 Japan (n=2), 12, 14 Germany (n=1), 13 Australia (n=1), 22 China (n=1) 17 and Singapore (n=1). 15 All studies were published in English and reported between 2012 and 2016. Sample size ranged from 12 to 249 individuals, with most studies including sample sizes smaller than 100 individuals (n=7). [12] [13] [14] [18] [19] [20] 22 In most studies (n=10), [12] [13] [14] [15] [16] [17] [18] [19] [20] 22 the mean age of patients was >50 years, and an equal proportion of men and women was recruited. Genitourinary cancer (n=9) [12] [13] [14] [15] [16] [18] [19] [20] [21] was the most evaluated cancer type in this review, followed by gastrointestinal (n=5), 12, 15, 16, 19, 21 breast (n=5), 12, 13, 15, 16, 19 lung (n=5) 15, 16, 19, 21, 22 and haematological cancer (n=3). 15, 19, 20 Most studies had a before-after design (n=5) 14, 15, 18, 19, 22 and only one 17 was a randomized controlled trial.
The assessment of the key components of pharmacist interventions showed that the studies were conducted at different outpatient settings, such as clinics, university hospitals and cancer centres or institutes. The main communication method with patients was faceto-face contact (72.7%). [12] [13] [14] [15] [16] 18, 19, 21 The duration of the interventions ranged from 2 to 45 months, with most studies (n=5) [16] [17] [18] 21, 22 reporting a follow-up time of less than 12 months. Regular contact with the patient (at least once a month) was reported in a study 18 ; other studies did not clearly describe this ( Only six studies 12, 13, 16, 17, 20, 21 included a control group that received usual care (eg, prescription analysis or supply of medicines).
The most commonly measured outcomes were rates of nausea and vomiting control (n=4) 12, 13, 16, 18 and patient satisfaction (n=3), 13, 15, 22 followed by quality of life (n=2), 13, 17 adverse drug reaction or adverse event frequency (n=2), 13, 21 drug-related problem frequency (n=1) 21 and anti-emesis drug costs (n=1). 12 Medication adherence (n=3), 16, 21, 22 knowledge-attitude-practice for chemotherapy (n=1), 17 awareness and knowledge regarding blood pressure management (n=1) 14 and adherence to laboratory parameter monitoring (n=1) 20 were measured as process indicators.
Pharmacist interventions significantly decreased adverse events and symptoms related to cancer (eg, nausea, vomiting or pain), as reported in all studies evaluating this outcome. 12, 13, 16, 18 All studies reported a significant improvement in satisfaction with pharmacist interventions, 13, 15, 22 patients' quality of life 13, 17 and anti-emesis drug costs. 12 Moreover, two studies 21, 22 reported a significant increase in medication adherence. All studies that measured other process indicators reported a significant improvement in knowledge-attitudepractice for chemotherapy, 17 awareness and knowledge regarding T A B L E 2 (Continued) (Continues) blood pressure management 14 and adherence to laboratory parameter monitoring 20 following pharmacist interventions.
Most studies stated the following limitations, a small sample size (n=5), 13, 14, [17] [18] [19] single-centre study (n=5) 16, 17, 19, 20, 22 and absence of a control group or presence of a retrospective control group (n=2). 13, 21 Other limitations were also reported, such as differences in baseline mean age between the control and intervention groups; 13 
| DISCUSSION
This is the first systematic review to measure the effect of pharmacist interventions on the management of adult outpatients with cancer using antineoplastic drugs. Our results indicated that there are few studies on this topic, with most of them being published from 2015. This is consistent with a current systematic review of pharmacist intervention models in oncology, which indicates that most research in this area is focused on inpatients. 10 In addition, most studies were conducted in the United States, Europe and Asia. No studies were performed in Latin America because oncology pharmacists were mainly involved in activities such as prescription review and preparation of antineoplastic drugs and their involvement in patient care is more recent. 23 In this systematic review, the most common cancers assessed were genitourinary, gastrointestinal, breast and lung cancers. Current estimates show that these cancers have the highest number of incident cases and mortality worldwide. 1 In addition, the mean age of patients in most studies was >50 years because the incidence of cancer rises dramatically with age, most likely due to a build-up of risks for specific cancers that increase with age. 24 Another relevant aspect in the assessment of pharmacist interventions is study design. For evidencebased practice, the randomized controlled trial is still considered as the gold standard for primary research; 25 however, only one study followed this approach, indicating that there is a need for high-quality evidence on this topic.
Adverse events related to the use of antineoplastic drugs are very common and may result in changes in pharmacotherapy and reduce the patients' quality of life. 26, 27 In this review, the main adverse events Single-centre study, small number of patients, absence of an independent reviewer to data collection, response bias, absence of randomized control group *Based on the DEPICT 2: (i) type of contact with the patient; (ii) action taken by pharmacist; (iii) pharmacist's autonomy to change prescription medication; (iv) support resources provided by pharmacist; and (v) frequency/duration of intervention.
ADR, adverse drug reaction; AE, adverse event; BP, blood pressure; CG, control group; CINV, chemotherapy-induced nausea and vomiting; CIPN, chemotherapy-induced peripheral neuropathy; CR, complete response; DRP, drug-related problems; IG, intervention group; KAP, knowledge-attitude-practice; NA, not applicable; NR, not reported; RDI, relative dose intensity.
T A B L E 2 (Continued) patients with cancer of the studies included in our review were elderly, had difficulty understanding the therapeutic regimen, experienced adverse reactions and/or used many drugs simultaneously; these factors have a significant correlation with poor adherence to antineoplastic drugs. 29 Thus, the pharmacists assessed patient's adherence and sought to optimize drug therapy by providing a simplified dosage schedule that is more appropriate to the patient's routine and habits. In addition, some studies provided patient education, self-management diaries and leaflets as strategies to increase medication adherence. In this review, almost all studies evaluating medication adherence have shown significant improvement in favour of pharmacist interventions.
All studies assessing the quality of life showed that the pharma- 12 showed that the inclusion of a pharmacist in oncology teams led to a better distribution of work among health professionals, allowing more patients to be assisted and generating a higher annual hospital revenue. In addition, the changes in prescription made by the pharmacist resulted in a reduction of cost for anti-emetic treatment by 16%. This type of evaluation should be considered an essential part of any clinical pharmacist service in order to provide the necessary evidence (to third-party payers, policymakers and governments) regarding the value of implementation and sustainability of these services. 33 The most common limitations reported in the studies appraised in this review were the small number of patients and the fact that they were performed in a single oncology centre. These factors may result in a poor representativeness of the population and statistical and data interpretation errors. 34 Another limitation observed in studies conducted at a single centre was the difficulty in avoiding contact and exchange of information between the control and intervention groups.
Besides, the absence of a control group or use of a retrospective control group was a recurrent limitation. Ribed et al. (2015) 21 reported that the use of a retrospective cohort was considered a more ethical option as the clinical pharmacy service was provided to all patients involved in the study. However, it is worth pointing out that the quality of the information documented in the period prior to pharmacist intervention is essential to avoid information bias. 35 Our findings indicate a need to design and report future research with a greater methodological rigour (eg, larger sample size, longer follow-up, multicentre and randomized controlled trial design study), for a more detailed description of pharmacist interventions (eg, support resources provided by pharmacist and frequency of contacts), and for an expanded focus on economic, clinical and humanistic outcomes in order to obtain more robust results to guide the pharmacists in the management of patients with cancer.
| Limitations
Our review has some limitations. First, although a comprehensive systematic search was performed, it is possible that some studies
were not captured because they were not indexed in the databases searched (eg, conference proceedings, dissertations or thesis). In addition, the care received by the intervention group was often poorly described, making it difficult to characterize the pharmacist intervention. Finally, it was not possible to perform a quantitative synthesis of the data in the form of meta-analysis owing to the heterogeneity of population, interventions and outcomes of the included studies.
| WHAT IS NEW AND CONCLUSION
In this review, most evidence on clinical pharmacist services for adult outpatients with cancer came from studies conducted in the United
States, including patients aged >50 years, and diagnosed as having 
